A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis

• Status: Completed
• Trial end date: 2013-01-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the efficacy of CP-690,550 as compared to etanercept and the safety of CP-690,550 for treatment of moderate to severe chronic plaque psoriasis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Etanercept; Tofacitinib

Criteria

Inclusion Criteria:

• Have had a diagnosis of plaque type psoriasis (psoriasis vulgaris);

• Have plaque-type psoriasis covering at least 10% of total body surface area

• Considered by dermatologist investigator to be a candidate for systemic therapy or phototherapy of psoriasis

Exclusion Criteria:

• Non-plaque or drug induced forms of psoriasis

• Cannot discontinue current systemic and/or topical therapies for the treatment of psoriasis

• Cannot discontinue phototherapy

• Any uncontrolled significant medical condition